Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Luc M. Berclaz [1 ]
Anton Burkhard-Meier [2 ]
Axel Lechner [1 ]
Michael Völkl [3 ]
Sinan E. Güler [1 ]
Sultan Abdel-Rahman [1 ]
Sina Mansoorian [1 ]
Wolfgang G. Kunz [4 ]
Thomas Knösel [5 ]
Martin Canis [6 ]
Michael von Bergwelt-Baildon [3 ]
Rolf D. Issels [1 ]
Dorit Di Gioia [2 ]
Lars H. Lindner [1 ]
机构：
[1] University Hospital,Department of Internal Medicine III
[2] LMU Munich,Deparment of Otorhinolaryngology
[3] German Cancer Consortium (DKTK),Department of Radiation Oncology
[4] Partner Site Munich,Department of Radiology
[5] University Hospital,Institute of Pathology
[6] LMU Munich,undefined
[7] University Hospital,undefined
[8] LMU Munich,undefined
[9] University Hospital,undefined
[10] LMU Munich,undefined
[11] LMU Munich,undefined
来源：
Cancer Immunology, Immunotherapy | / 74卷 / 6期
关键词：
Immunotherapy; Immune checkpoint inhibitors; Head and neck cancer; Regional hyperthermia;
D O I：
10.1007/s00262-025-04029-9
中图分类号：
学科分类号：
摘要：
We report a long-lasting response to the immune checkpoint inhibitor nivolumab in combination with regional hyperthermia (RHT) in a patient with recurrent metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) and negative programmed death ligand 1 (PD-L1) expression. Treatment was well tolerated with no local side effects. Tumor-related symptoms in the orbital and masticator area gradually decreased under treatment with nivolumab and RHT. Over the course of treatment, magnetic resonance imaging (MRI) showed a local tumor control in the heated tumor areas, while metastatic lesions developed in areas outside of the RHT field. This is the first case report demonstrating the feasibility and clinical potential of the addition of RHT in this patient collective with poor outcomes and low response rates to immune checkpoint inhibitors. RHT might be an additional tool to activate an immunogenic milieu responsive to immune checkpoint inhibitors.
引用
收藏
相关论文
共 50 条
  • [1] Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma
    Tardy, Magalie P.
    Di Mauro, Ilaria
    Ebran, Nathalie
    Refae, Sadal
    Bozec, Alexandre
    Benezery, Karen
    Peyrade, Frederic
    Guigay, Joel
    Sudaka-Bahadoran, Anne
    Badoual, Cecile
    Pedeutour, Florence
    Saada-Bouzid, Esma
    ORAL ONCOLOGY, 2018, 80 : 104 - 107
  • [2] Combination of anti-PD-1 inhibitors with radiotherapy for recurrent/metastatic squamous cell carcinoma in the head and neck region
    Tamaskovics, Balint
    Haussmann, Jan
    Neuwahl, Judith
    Jazmati, Danny
    Plettenberg, Christian
    Althaus, Laurenz
    Boelke, Edwin
    Matuschek, Christiane
    Budach, Wilfried
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S166 - S166
  • [3] Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma
    Fujiwara, Motohiro
    Shimada, Wataru
    Yokoyama, Minato
    Koyanagi, Anri
    Shintaku, Hiroshi
    Fukuda, Shohei
    Waseda, Yuma
    Tanaka, Hajime
    Yoshida, Soichiro
    Fujii, Yasuhisa
    IJU CASE REPORTS, 2024, 7 (04) : 293 - 296
  • [4] Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
    Zargar, Mahdi
    McFarlane, Thomas
    Chan, Kelvin K. W.
    Wong, William W. L.
    ONCOLOGIST, 2018, 23 (02): : 225 - 233
  • [5] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
    Klein, Oliver
    JAMA ONCOLOGY, 2024, 10 (01) : 143 - 144
  • [6] Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Guiard, Emeline
    Clatot, Florian
    Even, Caroline
    Perreard, Marion
    Abdeddaim, Cyril
    Johnson, Alison
    Vauleon, Elodie
    Rambeau, Audrey
    EUROPEAN JOURNAL OF CANCER, 2021, 159 : 125 - 132
  • [7] PD-L1 expression in recurrent head and neck squamous cell carcinoma
    Delafoy, Alice
    Uguen, Arnaud
    Lemasson, Gilles
    Conan-Charlet, Virginie
    Pradier, Olivier
    Lucia, Francois
    Schick, Ulrike
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (01) : 343 - 351
  • [8] PD-L1 expression in recurrent head and neck squamous cell carcinoma
    Delafoy, A.
    Uguen, A.
    Key, S.
    Lucia, F.
    Lemasson, G.
    Abgral, R.
    Dissaux, G.
    Pradier, O.
    Schick, U.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S627 - S628
  • [9] PD-L1 expression in recurrent head and neck squamous cell carcinoma
    Alice Delafoy
    Arnaud Uguen
    Gilles Lemasson
    Virginie Conan-Charlet
    Olivier Pradier
    François Lucia
    Ulrike Schick
    European Archives of Oto-Rhino-Laryngology, 2022, 279 : 343 - 351
  • [10] PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
    Evrard, D.
    Hourseau, M.
    Couvelard, A.
    Paradis, V.
    Gauthier, H.
    Raymond, E.
    Halimi, C.
    Barry, B.
    Faivre, S.
    ONCOIMMUNOLOGY, 2020, 9 (01):
12345